MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000544936

Медицинская библиотека · American journal of nephrology · 2025

Pharmacokinetic Properties of Dapagliflozin in Patients with Stage 4 Chronic Kidney Disease.

Xu Zhongyuan, Li Dan, Xie Di, Gu Ancheng, Yang Yaya, Guo Zhijian, Huang Xianglan, Li Jun, Wang Jun, Zhang Lei, Hu Bianxiang, Yang Xiaobing, Huang Yan, Cao Wanwen, Wei Yerong, He Jiali, Xu Zhongyuan, Liang Min

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

The pharmacokinetic data on dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, are limited in patients with severe renal impairment. We aimed to evaluate the pharmacokinetic properties and safety of dapagliflozin in patients with chronic kidney disease (CKD) stage 4.

METHODS

This was a single-center, open-label, pharmacokinetic trial involving single, and multiple doses. Patients with an estimated glomerular filtration rate (eGFR) of 15-<30 mL/min/1.73 m2 were enrolled. The single-dose group received 10 mg of oral dapagliflozin once daily, while the multiple-dose group received 10 mg daily for 5 days. Pharmacokinetic parameters, pharmacodynamic response, and tolerability were assessed.

RESULTS

A total of 12 participants completed the single-dose study, and 9 participants completed the multiple-dose study. The mean eGFR was 23.4 and 23.2 mL/min/1.73 m2 in single- and multiple-dose group, respectively. In the single-dose group, dapagliflozin was rapidly absorbed and metabolized to produce dapagliflozin 3-O-glucuronide (D3OG), with a mean Tmax of 0.7 h and 1.8 h, and a mean T1/2 of 16.7 h and 14.9 h, respectively. Participants with an eGFR of 15-24 mL/min/1.73 m2 exhibited higher AUC0-∞ and mean residence time for D3OG compared to those with an eGFR of 25-30 mL/min/1.73 m2. In the multiple-dose group, there was no significant accumulation of dapagliflozin, as indicated by the ratio of AUCTau (918.6 ± 155.2 h × ng/mL) to AUC0-24 h (917.1 ± 154.7 h × ng/mL) was close to 1. In the multiple-dose group, urinary albumin/creatinine ratio decreased by 21% and 24-h urinary protein decreased by 23% from baseline to 24 h after the last dose.

CONCLUSION

In conclusion, no clinically significant accumulation of dapagliflozin was observed in patients with stage 4 CKD.

Для цитирования: Xu Zhongyuan, Li Dan, Xie Di, Gu Ancheng, Yang Yaya, Guo Zhijian, Huang Xianglan, Li Jun, Wang Jun, Zhang Lei, Hu Bianxiang, Yang Xiaobing, Huang Yan, Cao Wanwen, Wei Yerong, He Jiali, Xu Zhongyuan, Liang Min. Pharmacokinetic Properties of Dapagliflozin in Patients with Stage 4 Chronic Kidney Disease.. American journal of nephrology. 2025. DOI: 10.1159/000544936.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.